Accurate diagnosis of mesothelioma: more important than ever

Our plain-English summary of Accurate diagnosis of mesothelioma: more important than ever, by T.C. Allen (Archives of Pathology & Laboratory Medicine, 2013).

The study

• Author: T.C. Allen
• Journal: Archives of Pathology & Laboratory Medicine
• Published: 2013;137(5):601-2
• Type of article: Editorial, Comment
• Cited by: 4 articles, as counted by NIH iCite
• Read it: PubMed · Publisher

Summary of the article

In this editorial, the author argued that accurate pathologic diagnosis of diffuse malignant mesothelioma (DMM) had become more important than ever. He described DMM as a diagnosis that is difficult to make with certainty and that carries heavy prognostic and legal weight. The disease is rare, its mimics are common, and few pathologists gain familiarity with it; even expert pathologists find some cases extremely challenging. He noted that only 20% of patients respond to cisplatin, that surgery and radiotherapy fare no better, and that conventional treatment often achieves no better result than supportive care. Survival rates remain extremely low, and reported long-term survival frequently reflects misdiagnosis. DMM incidence and mortality were predicted to continue to increase. The author pointed to several developments: research into the molecular mechanisms by which asbestos causes DMM, the search for molecular biomarkers, novel intrapleural and immune-based therapies, prevention efforts prompted by the long latency of asbestos-related DMM, and a trend toward standardized treatment, guidelines and registries. He argued that such studies and guidelines would be useless, or even dangerous, unless they were based on accurately diagnosed cases. He introduced the International Mesothelioma Interest Group's 2012 update of its 2009 guidelines for pathologic diagnosis of malignant mesothelioma, published in the same issue, and described it as a timely and welcome reference for pathologists.

PubMed has no abstract for this study, and the article doesn't print one. We wrote this summary from the full article with the help of AI. It is not the authors' wording.

In plain English

This is a short editorial, not a research study, and it reports no new data. The author argued that accurately diagnosing diffuse malignant mesothelioma (DMM) has never been more important. The author described DMM as rare, hard to diagnose and easily confused with more common conditions, noting that a pathologist can spend a career without ever diagnosing it. Citing other publications, the author wrote that only 20% of DMM patients show any response to the drug cisplatin and that the outlook for patients is dismal. The author also wrote that reported cases of long-term survival frequently reflect misdiagnosis. The author pointed to ongoing research into molecular markers, new treatments and treatment standards. The author warned that studies, guidelines and standards would be useless, and worse, dangerous, unless they were based on accurately diagnosed cases. The editorial introduced a 2012 update, published in the same journal issue, of the International Mesothelioma Interest Group's 2009 guidelines for the pathologic diagnosis of malignant mesothelioma.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: editorial (opinion piece; no original data)
• Main results:
  • The author stated that DMM is rare and its mimics are common, so that a pathologist can spend a whole career without diagnosing it.
  • Citing other publications (not data from this editorial), the author wrote that only 20% of DMM patients show any response to cisplatin.
  • The author wrote that reported cases of long-term survival with DMM frequently reflect misdiagnosis.
  • The author argued that studies, guidelines and standards would be useless, and even dangerous, unless they were based on accurately diagnosed DMM.
  • The editorial introduced a 2012 update, in the same journal issue, of the International Mesothelioma Interest Group's 2009 guidelines for pathologic diagnosis of malignant mesothelioma.
• The authors' conclusion: The author concluded that accurate diagnosis of DMM has never been more important.

Topics

The National Library of Medicine indexes this study under subjects our site covers: Lung cancer, Mesothelioma.

Medical terms in this study, explained in our Lexicon: Mesothelioma, Malignant Mesothelioma, Cisplatin, Misdiagnosis, Biomarker, Latency.

Related studies

• Endemic malignant mesothelioma: exposure to erionite is more important than genetic factors — M. Metintas, G. Hillerdal, et al. (2010)
• The clinical diagnosis of asbestosis in this century requires more than a chest radiograph — R.M. Ross (2003)
• The aetiology of mesothelioma: are risk factors other than asbestos exposure important? — R. Hubbard (1997)
• Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses — J.M. Porcel, A. Esquerda, et al. (2014)
• Genotoxicity of carbon nanofibers: are they potentially more or less dangerous than carbon nanotubes or asbestos? — E.R. Kisin, A.R. Murray, et al. (2011)
• BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas — N. Leblay, F. Leprêtre, et al. (2017)

Browse more research in Archives of Pathology & Laboratory Medicine, or return to medical research.